Adma Biologics (ADMA) Finished Goods (2017 - 2026)
Adma Biologics' (ADMA) quarterly Finished Goods came in at $52.1 million in Q4 2025, up 8.18% YoY from $48.1 million in Q4 2024, and down 19.1% on a QoQ basis from $64.3 million in Q3 2025.
Adma Biologics (ADMA) Finished Goods (2017 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 9 years of Finished Goods data on file, last reported at $52.1 million in Q4 2025.
- Quarterly Finished Goods rose 8.18% year-over-year to $52.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.1 million (up 8.18% YoY) and the FY2025 annual result came in at $52.1 million, up 8.18% from the prior year.
- Finished Goods eased to $52.1 million in Q4 2025, from $64.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $70.3 million in Q4 2023 to a low of $17.5 million in Q2 2021.
- A 5-year average of $51.5 million and a median of $52.3 million in 2023 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2022 — Finished Goods soared 257.16% — and 2025, when it tumbled 32.47%.
- Tracing ADMA's Finished Goods over 5 years: stood at $29.0 million in 2021, then soared by 101.6% to $58.5 million in 2022, then rose by 20.22% to $70.3 million in 2023, then sank by 31.54% to $48.1 million in 2024, then gained by 8.18% to $52.1 million in 2025.
- The last three Finished Goods figures came in at $52.1 million (Q4 2025), $64.3 million (Q3 2025), and $47.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.57 Mn |
| Dec 31, 2025 | 52.06 Mn |
| Sep 30, 2025 | 64.35 Mn |
| Jun 30, 2025 | 47.92 Mn |
| Mar 31, 2025 | 46.59 Mn |
| Dec 31, 2024 | 48.12 Mn |
| Sep 30, 2024 | 63.07 Mn |
| Jun 30, 2024 | 67.76 Mn |
| Mar 31, 2024 | 68.99 Mn |
| Dec 31, 2023 | 70.29 Mn |
| Sep 30, 2023 | 54.98 Mn |
| Jun 30, 2023 | 52.34 Mn |
| Mar 31, 2023 | 46.15 Mn |
| Dec 31, 2022 | 58.47 Mn |
| Sep 30, 2022 | 67.62 Mn |
| Jun 30, 2022 | 56.62 Mn |
| Mar 31, 2022 | 47.97 Mn |
| Dec 31, 2021 | 29.00 Mn |
| Sep 30, 2021 | 18.93 Mn |
| Jun 30, 2021 | 17.48 Mn |